ASH 2019 | Nivo and dara +/- cyclophosphamide in R/R MM
Niels van de Donk, MD, PhD, VU University Medical Center, Amsterdam, The Netherlands, discusses a prospective, multicenter, phase II trial (NCT03184194). This study investigated the efficacy and safety of daratumumab combined with nivolumab, with or without low-dose cyclophosphamide, in patients with relapsed/refractory multiple myeloma (MM). Results indicate that the combination of daratumumab and nivolumab may be a new therapeutic regimen with an acceptable safety profile. However, the addition of low-dose cyclophosphamide did not improve efficacy, and increased the frequency of infections and hematologic toxicity. Therefore, the nivolumab-daratumumab regimen was selected for further evaluation. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
